Tarceva Pancreatic Cancer Survival Merits Approval, More Study Of Dosing
Executive Summary
Genentech/OSI should study sequential dosing of its epidermal growth factor receptor inhibitor Tarceva and Lilly's Gemzar, FDA and Oncologic Drugs Advisory Committee members suggested in recommending supplemental approval of erlotinib for treatment of pancreatic cancer Sept. 13
You may also be interested in...
ODAC Veterans Disagree On Value Of Public Hearing At Panel Meetings
Current and former chairs of FDA’s Oncologic Drugs Advisory Committee debate the usefulness of the public hearing and its impact on committee deliberations.
Genentech/OSI Touting Tarceva Pancreatic Cancer Overall Survival Benefit
Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer
Genentech/OSI Touting Tarceva Pancreatic Cancer Overall Survival Benefit
Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer